Get the Stockscreener App
15.99
1.27%
0.20
After Hours:
15.99
Centessa Pharmaceuticals Plc Adr stock is traded at $15.99, with a volume of 480.27K.
It is up +1.27% in the last 24 hours and up +18.44% over the past month.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
See More
Previous Close:
$15.79
Open:
$15.73
24h Volume:
480.27K
Relative Volume:
0.88
Market Cap:
$2.04B
Revenue:
-
Net Income/Loss:
$-151.09M
P/E Ratio:
-8.8343
EPS:
-1.81
Net Cash Flow:
$-160.51M
1W Performance:
+2.70%
1M Performance:
+18.44%
6M Performance:
+41.50%
1Y Performance:
+147.14%
1-Day Range:
$15.73
$16.62
1-Week Range:
$15.20
$16.62
52-Week Range:
$5.15
$17.59
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals Plc Adr
Sector
Industry
Phone
44 7391 789784
Address
3RD FLOOR, ALTRINCHAM, CHESHIRE
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-23 | Initiated | SVB Securities | Outperform |
| Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
| Feb-11-22 | Initiated | Goldman | Neutral |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Latest News
Centessa Pharmaceuticals plc ADR (CNTA) shows promising results - US Post News
Ratios Uncovered: Breaking Down Centessa Pharmaceuticals plc ADR (CNTA)’s Trailing Twelve Months Metrics - The Dwinnex
Centessa Pharmaceuticals executive sells over $260k in company stock By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals executive sells over $260k in company stock By Investing.com - Investing.com UK
Centessa Pharmaceuticals plc ADR [CNTA] Shares Rise 2.15 % on Thursday - Knox Daily
Centessa Pharmaceuticals plc ADR (CNTA) is looking forward to a strong quarter - SETE News
Centessa's ORX142 shows promise for treating daytime sleepiness - Investing.com
Monitoring Accenture plc (ACN) after recent insider movements - Knox Daily
ALLE stock rated an Underweight by Barclays - Knox Daily
Understanding the Risks of Investing in BranchOut Food Inc (BOF) - Knox Daily
EON Resources Inc. [EONR] Investment Guide: What You Need to Know - Knox Daily
Analysts review Reneo Pharmaceuticals Inc’s rating - Knox Daily
Analyzing Pineapple Energy Inc (PEGY) After Recent Trading Activity - Knox Daily
Investing in nVent Electric plc (NVT): What You Must Know - Knox Daily
Peraso Inc’s latest rating changes from various analysts - Knox Daily
Chief Executive Officer, Scots-Knight Denise sold 60,046 shares of Mereo Biopharma Group Plc ADR [MREO] - Knox Daily
Verona Pharma Plc ADR [VRNA] President and CEO makes an insider sale of 600,000 shares worth $2.25 million. - Knox Daily
Examining the Potential Price Growth of Biomarin Pharmaceutical Inc. (BMRN) - Knox Daily
Monitoring Ultragenyx Pharmaceutical Inc. (RARE) after recent insider movements - Knox Daily
Investing in BrightSpire Capital Inc (BRSP) Is Getting More Attractive - Knox Daily
Citigroup analysts initates a Buy rating for Crinetics Pharmaceuticals Inc (CRNX) - Knox Daily
An Analysis of Trane Technologies plc (TT)’s Potential Price Growth - Knox Daily
Conduit Pharmaceuticals Inc [CDT] Insider Activity: An Update for Investors - Knox Daily
TD Cowen’s latest rating for KBR stock - Knox Daily
Investing in Trio Petroleum Corp. (TPET) Is Getting More Attractive - Knox Daily
Everi Holdings Inc (EVRI) gets rating Resumed from B. Riley Securities - Knox Daily
Recent Insider Activity Could Benefit Janus Henderson Group plc (JHG) - Knox Daily
JCI (Johnson Controls International plc) may reap gains as insiders became active recently - Knox Daily
MULN’s latest rating updates from top analysts. - Knox Daily
ARS Pharmaceuticals Inc [SPRY] Investment Appeal on the Rise - Knox Daily
Monitoring Perrigo Company plc (PRGO) after recent insider movements - Knox Daily
Is Centessa Pharmaceuticals plc ADR (CNTA) worth investing in despite its undervalued state? - US Post News
Market Insight: Centessa Pharmaceuticals plc ADR (CNTA)’s Notable Gain, Closing at 16.58 - The Dwinnex
Centessa Pharmaceuticals CEO sells over $900k in company stock - Investing.com
Centessa Pharmaceuticals CEO sells over $900k in company stock - Investing.com India
Chief Business Officer Weinhoff Gregory M sale 30,000 shares of Centessa Pharmaceuticals plc ADR [CNTA] - Knox Daily
Arcadium Lithium PLC [ALTM] Director makes an insider purchase of 5,000 shares worth 16150.0. - Knox Daily
Taking on analysts’ expectations and winning: Centessa Pharmaceuticals plc ADR (CNTA) - SETE News
Market Watch Highlights: Centessa Pharmaceuticals plc ADR (CNTA) Ends on an Downturn Note at 16.28 - The Dwinnex
Are Centessa Pharmaceuticals plc ADR’shares a good deal? - US Post News
Recent Insider Activity Suggests Potential Gains for Centessa Pharmaceuticals plc ADR (CNTA) - Knox Daily
Goldman gives a Buy recommendation for Ultragenyx Pharmaceutical Inc. (RARE) - Knox Daily
Centessa Pharmaceuticals plc ADR (CNTA) Stock: Navigating a Year of Volatility - The InvestChronicle
Get in on Centessa Pharmaceuticals plc ADR’s (CNTA) buy-in window today! - SETE News
Centessa Pharmaceuticals CEO sells shares worth over $2.89 million - Investing.com India
Centessa Pharmaceuticals CBO sells shares worth $510,000 - Investing.com India
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares - GlobeNewswire Inc.
Centessa Pharmaceuticals CBO sells shares worth $510,000 - Investing.com
Centessa Pharmaceuticals CEO sells shares worth over $2.89 million - Investing.com
Centessa Pharmaceuticals launches $150 million ADS offering - Investing.com India
New additions to Roth MKM’s ADR portfolio for September - MSN
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):